Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435843 | 0.82 | HTT (0.43) | ALDH1A1MAPTGLAMEN1KMT2A | |
| SCHEMBL4435846 | 0.82 | HTT (0.43) | ALDH1A1MAPTGLAMEN1KMT2A | |
| SCHEMBL3580938 | 0.80 | MAPT (0.46) | ALDH1A1MAPTPOLBGLAMEN1 | |
| SCHEMBL6645257 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1MAPTPOLBKMT2ALMNA | |
| SCHEMBL1645440 | 0.78 | NPC1 (0.42) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL15142139 | 0.78 | ALDH1A1 (0.36) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL4617811 | 0.78 | ALDH1A1 (0.36) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4279302 | 0.73 | MAPT (0.43) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4035324 | 0.73 | ALDH1A1 (0.60) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL2644412 | 0.72 | MAPT (0.34) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958873-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20180282352-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2015073528-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1893605-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103449-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | ALDH1A1 3439/4885MAPT 943/4885POLB 691/4885 |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | ALDH1A1 3439/4885MAPT 943/4885POLB 691/4885 |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | TIE1, TEK, FLT1 | ALDH1A1 1756/4885MAPT 3163/4885POLB 981/4885 |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | ALDH1A1 2198/4885MAPT 1426/4885POLB 210/4885 |
| US-20180282352-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | ALDH1A1 3439/4885MAPT 943/4885POLB 691/4885 |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | ALDH1A1 3439/4885MAPT 943/4885POLB 691/4885 |
| US-11242361-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | ALDH1A1 3439/4885MAPT 943/4885POLB 691/4885 |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | ALDH1A1 3439/4885MAPT 943/4885POLB 691/4885 |
| US-11958873-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | ALDH1A1 3439/4885MAPT 943/4885POLB 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.